Empowering Precision Diagnostics
Bringing ImmunoGuide ELISA technologies to Europe and beyond
Validated ELISA kits for therapeutic drug monitoring and anti-drug antibody detection, for clinical labs, research institutions, and biotech teams. For Research Use Only.
Featured ELISA kits
Drug-level and anti-drug antibody assays across TNF-alpha, VEGF, EGFR, HER2, and more.
ADALIMUMAB ELISA
Analyte: Adalimumab
View kitADALIMUMAB ELISA (MAB-BASED)
Analyte: Adalimumab
View kitAFLIBERCEPT ELISA
Analyte: Aflibercept
View kitANTIBODY TO ADALIMUMAB ELISA
Analyte: Adalimumab
View kitANTIBODY TO BEVACIZUMAB ELISA
Analyte: Bevacizumab
View kitANTIBODY TO CERTOLIZUMAB PEGOL ELISA
Analyte: Certolizumab Pegol
View kitFrom our journal
Background on ELISA methods, therapeutic drug monitoring, anti-drug antibodies, and assay validation.
Adalimumab Biosimilar Switches in Pediatric IBD: What the Trough Level Drop Means for Your Monitoring Protocol
Two 2026 multicenter studies confirm that nonmedical adalimumab biosimilar switches in children with IBD generally maintain disease control, but trough levels fell significantly post-switch in one cohort, and neither study included systematic TDM or ADA testing. This article examines what that measurement gap means for laboratory monitoring protocols around pediatric biosimilar switches.
When ADA Incidence Misleads: Interpreting Highly Sensitive Immunogenicity Assays in Biosimilar Programs
A biosimilar immunogenicity report showing a 42 percent ADA rate against a reference biologic's labeled 6 percent is not automatically a safety signal. The number is shaped as much by assay sensitivity, drug tolerance, and platform architecture as by the patient's immune response. This article explains how to interpret highly sensitive ADA data in biosimilar programs and what clinical switching data reveal about the stakes of getting it wrong.
Rituximab Biosimilars in AAV: What Six-Month Real-World Data Tell Monitoring Scientists
The BRAVO multicenter cohort study found no statistically significant differences in remission rates, relapse rates, or serious adverse events between biosimilar and originator rituximab at six months in granulomatosis with polyangiitis and microscopic polyangiitis. For laboratories supporting drug-level and immunogenicity testing in biosimilar-treated AAV populations, the findings reinforce rather than reduce the case for structured pharmacokinetic and pharmacodynamic monitoring. B cell depletion kinetics, ANCA serology, serum drug levels, and anti-drug antibody assays each remain indispensable endpoints regardless of which rituximab formulation the patient receives.